

Supplemental Table. Clinical characteristics of study cohort

	Cetuximab + Bevacizumab (N=11)	Cetuximab + Bevacizumab + Irinotecan (N=22)	Total (N=33)
Median age (years)	53 (32-67)	60 (39-74)	58 (32-74)
Sex			
<i>Male</i>	6	14	20
<i>Female</i>	5	8	13
Age	58	59	58
Received previous FOLFOX	8	20	28
Response			
<i>Progression of disease</i>	1	5	6
<i>Stable disease</i>	2	12	20
<i>Partial response</i>	8	5	7